Department of Obstetrics and Gynecology, St Michael's Hospital, Toronto, Ontario, Canada.
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Am J Gastroenterol. 2016 May;111(5):665-70. doi: 10.1038/ajg.2016.43. Epub 2016 Mar 15.
Non-alcoholic fatty liver disease (NAFLD) is mediated by insulin resistance, as is gestational diabetes mellitus (GDM). NAFLD has not been studied in relation to GDM. The objective of this study was to assess the association between first-trimester sonographic findings of NAFLD, and both dysglycemia and GDM in mid-pregnancy.
We followed a prospective cohort design at a large obstetrics clinic in Toronto, Ontario with 476 women enrolled in early pregnancy. NAFLD was assessed by ultrasound at 11-14 weeks gestation, and standardized images were independently scored by two ultrasonographers for the presence of hepatorenal contrast (one finding) and/or blurring of the intrahepatic vessels (one finding), relative to neither being present. Logistic regression analysis was used to generate odds ratios (ORs) and 95% confidence interval (CI) for the relation between 0, 1, or 2 sonographic findings of NAFLD and the composite outcome of impaired fasting glucose, impaired glucose tolerance, or GDM at 24-28 weeks gestation, determined by a fasting 75-g oral glucose tolerance test. ORs were adjusted (aOR) for maternal age, ethnicity, first-degree relative with type 2 DM, body mass index (BMI) at 11-14 weeks gestation, and change in BMI from 11-14 to 24-28 weeks gestation.
Fifty out of 476 women (10.5%) developed the composite outcome. The presence of 1 (aOR 2.0, 95% CI: 1.0-4.1) or 2 (aOR 2.9, 95% CI: 1.0-18.4) sonographic features of NAFLD predicted the composite outcome. Limiting the analysis to ≥1 feature vs. none, the aOR was 2.2 (95% CI: 1.1-4.3).
Sonographic assessment of NAFLD is a semiquantitative measure, with limited ability to detect small amounts of hepatic steatosis, or to distinguish various stages of NAFLD. First-trimester sonographic evidence of NAFLD predicts dysglycemia in mid-pregnancy.
非酒精性脂肪性肝病(NAFLD)是由胰岛素抵抗引起的,妊娠期糖尿病(GDM)也是如此。尚未研究 NAFLD 与 GDM 之间的关系。本研究的目的是评估孕早期超声检查发现的 NAFLD 与妊娠中期的糖代谢异常和 GDM 之间的关系。
我们在安大略省多伦多的一家大型妇产科诊所进行了前瞻性队列设计,共有 476 名孕妇在孕早期入组。在 11-14 孕周时通过超声检查评估 NAFLD,两名超声医师独立对存在肝-肾对比(一个发现)和/或肝内血管模糊(一个发现)的情况进行评分,相对于两者均不存在。使用逻辑回归分析生成比值比(OR)和 95%置信区间(CI),用于评估 0、1 或 2 个超声 NAFLD 发现与妊娠 24-28 周时的空腹血糖受损、葡萄糖耐量受损或 GDM 的复合结局之间的关系,通过空腹 75g 口服葡萄糖耐量试验确定。OR 经产妇年龄、种族、一级亲属 2 型糖尿病、11-14 孕周时的体重指数(BMI)以及 11-14 至 24-28 孕周时 BMI 的变化(aOR)调整。
476 名女性中有 50 名(10.5%)出现了复合结局。存在 1 个(aOR 2.0,95%CI:1.0-4.1)或 2 个(aOR 2.9,95%CI:1.0-18.4)超声 NAFLD 特征预测了复合结局。将分析仅限于≥1 个特征与无特征相比,aOR 为 2.2(95%CI:1.1-4.3)。
NAFLD 的超声评估是一种半定量测量方法,检测少量肝脂肪变性的能力有限,也无法区分 NAFLD 的各个阶段。孕早期超声检查发现的 NAFLD 可预测妊娠中期的糖代谢异常。